The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
复制标题
DOI：
10.1517/14712598.2011.557657
复制
发表时间：
2011-03-01
影响因子：
4.6
通讯作者：
Spratlin, Jennifer
中科院分区：
文献类型：
--
作者：
Mulder, Karen;Scarfe, Andrew;Spratlin, Jennifer
涵盖的领域：该综述重点关注BV在结直肠癌中的使用，讨论了支持其使用增加的临床试验数据，并探讨了其局限性。读者将获得对试验数据的简洁描述，这些数据证明转移性结直肠癌（mCRC）的适度生存获益以及BV在辅助治疗中缺乏获益。一个审查常见的BV毒性和讨论可能的BV耐药机制也provided.Expert意见：虽然BV已证明有效的mCRC，有迫切需要提高其作用机制的理解和BV耐药的发展。此外，需要描绘BV疗效和毒性的预测标志物。
Areas covered: The review focuses on the use of BV in colorectal cancer, discusses the clinical trial data supporting its increasing use and explores its limitations. Readers will gain a succinct description of the trial data demonstrating a modest survival benefit in metastatic colorectal cancer (mCRC) and the lack of benefit of BV when utilized in the adjuvant setting. A review of common BV toxicities and a discussion about possible BV resistance mechanisms are also provided.Expert opinion: Although BV has demonstrated efficacy in mCRC, there is an urgent need to improve the understanding of its mechanism of action and the development of BV resistance. Furthermore, there is a need for delineating predictive markers of BV efficacy and toxicity.